3u1j › Citations

Ligand-bound structures of the dengue virus protease reveal the active conformation.

Noble CG, Seh CC, Chao AT, Shi PY
J Virol 86 438-46 (2012)
Cited: 126 times
EuropePMC logo PMID: 22031935

Abstract

Dengue is a mosquito-borne viral hemorrhagic disease that is a major threat to human health in tropical and subtropical regions. Here we report crystal structures of a peptide covalently bound to dengue virus serotype 3 (DENV-3) protease as well as the serine-protease inhibitor aprotinin bound to the same enzyme. These structures reveal, for the first time, a catalytically active, closed conformation of the DENV protease. In the presence of the peptide, the DENV-3 protease forms the closed conformation in which the hydrophilic β-hairpin region of NS2B wraps around the NS3 protease core, in a manner analogous to the structure of West Nile virus (WNV) protease. Our results confirm that flavivirus proteases form the closed conformation during proteolysis, as previously proposed for WNV. The current DENV-3 protease structures reveal the detailed interactions at the P4' to P3 sites of the substrate. The new structural information explains the sequence preference, particularly for long basic residues in the nonprime side, as well as the difference in substrate specificity between the WNV and DENV proteases at the prime side. Structural analysis of the DENV-3 protease-peptide complex revealed a pocket that is formed by residues from NS2B and NS3; this pocket also exists in the WNV NS2B/NS3 protease structure and could be targeted for potential antivirus development. The structural information presented in the current study is invaluable for the design of specific inhibitors of DENV protease.

Reviews - 3u1j mentioned but not cited (4)

  1. The A-Z of Zika drug discovery. Mottin M, Borba JVVB, Braga RC, Torres PHM, Martini MC, Proenca-Modena JL, Judice CC, Costa FTM, Ekins S, Perryman AL, Horta Andrade C. Drug Discov Today 23 1833-1847 (2018)
  2. Current Trends and Limitations in Dengue Antiviral Research. Obi JO, Gutiérrez-Barbosa H, Chua JV, Deredge DJ. Trop Med Infect Dis 6 180 (2021)
  3. Proteases from dengue, West Nile and Zika viruses as drug targets. Nitsche C. Biophys Rev 11 157-165 (2019)
  4. Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach. Norshidah H, Leow CH, Ezleen KE, Wahab HA, Vignesh R, Rasul A, Lai NS. Front Cell Infect Microbiol 13 1061937 (2023)

Articles - 3u1j mentioned but not cited (9)

  1. Ligand-bound structures of the dengue virus protease reveal the active conformation. Noble CG, Seh CC, Chao AT, Shi PY. J Virol 86 438-446 (2012)
  2. An In-Silico Investigation of Phytochemicals as Antiviral Agents Against Dengue Fever. Powers CN, Setzer WN. Comb Chem High Throughput Screen 19 516-536 (2016)
  3. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side. Lin KH, Ali A, Rusere L, Soumana DI, Kurt Yilmaz N, Schiffer CA. J Virol 91 e00045-17 (2017)
  4. Dengue Protease Substrate Recognition: Binding of the Prime Side. Lin KH, Nalivaika EA, Prachanronarong KL, Yilmaz NK, Schiffer CA. ACS Infect Dis 2 734-743 (2016)
  5. Ligand Accessibility Insights to the Dengue Virus NS3-NS2B Protease Assessed by Long-Timescale Molecular Dynamics Simulations. Kronenberger T, Sá Magalhães Serafim M, Kumar Tonduru A, Gonçalves Maltarollo V, Poso A. ChemMedChem 16 2524-2534 (2021)
  6. Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease. Uday RVS, Misra R, Harika A, Dolui S, Saha A, Pal U, Ravichandiran V, Maiti NC. PLoS One 16 e0257206 (2021)
  7. Cold spots are universal in protein-protein interactions. Gurusinghe SNS, Oppenheimer B, Shifman JM. Protein Sci 31 e4435 (2022)
  8. Dengue virus protease activity modulated by dynamics of protease cofactor. Lee WHK, Liu W, Fan JS, Yang D. Biophys J 120 2444-2453 (2021)
  9. Dual function of Zika virus NS2B-NS3 protease. Shiryaev SA, Cieplak P, Cheltsov A, Liddington RC, Terskikh AV. PLoS Pathog 19 e1011795 (2023)


Reviews citing this publication (28)

  1. Ten years of dengue drug discovery: progress and prospects. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. Antiviral Res 100 500-519 (2013)
  2. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Luo D, Vasudevan SG, Lescar J. Antiviral Res 118 148-158 (2015)
  3. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Boldescu V, Behnam MAM, Vasilakis N, Klein CD. Nat Rev Drug Discov 16 565-586 (2017)
  4. Structural biology of dengue virus enzymes: towards rational design of therapeutics. Noble CG, Shi PY. Antiviral Res 96 115-126 (2012)
  5. Targeting dengue virus NS4B protein for drug discovery. Xie X, Zou J, Wang QY, Shi PY. Antiviral Res 118 39-45 (2015)
  6. Zika Virus Protease: An Antiviral Drug Target. Kang C, Keller TH, Luo D. Trends Microbiol 25 797-808 (2017)
  7. Peptides as Therapeutic Agents for Dengue Virus. Chew MF, Poh KS, Poh CL. Int J Med Sci 14 1342-1359 (2017)
  8. The flavivirus protease as a target for drug discovery. Brecher M, Zhang J, Li H. Virol Sin 28 326-336 (2013)
  9. West Nile virus drug discovery. Lim SP, Shi PY. Viruses 5 2977-3006 (2013)
  10. Functional interplay among the flavivirus NS3 protease, helicase, and cofactors. Li K, Phoo WW, Luo D. Virol Sin 29 74-85 (2014)
  11. Intervention strategies for emerging viruses: use of antivirals. Debing Y, Jochmans D, Neyts J. Curr Opin Virol 3 217-224 (2013)
  12. The Potential Use of Natural and Structural Analogues of Antimicrobial Peptides in the Fight against Neglected Tropical Diseases. Lewies A, Wentzel JF, Jacobs G, Du Plessis LH. Molecules 20 15392-15433 (2015)
  13. Strategies Towards Protease Inhibitors for Emerging Flaviviruses. Nitsche C. Adv Exp Med Biol 1062 175-186 (2018)
  14. Structurally- and dynamically-driven allostery of the chymotrypsin-like proteases of SARS, Dengue and Zika viruses. Lim L, Gupta G, Roy A, Kang J, Srivastava S, Shi J, Song J. Prog Biophys Mol Biol 143 52-66 (2019)
  15. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Samrat SK, Xu J, Li Z, Zhou J, Li H. Pathogens 11 293 (2022)
  16. Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review. Wahaab A, Mustafa BE, Hameed M, Stevenson NJ, Anwar MN, Liu K, Wei J, Qiu Y, Ma Z. Viruses 14 44 (2021)
  17. Imidazolidinones and Imidazolidine-2,4-diones as Antiviral Agents. Swain SP, Mohanty S. ChemMedChem 14 291-302 (2019)
  18. Insights into Structures and Dynamics of Flavivirus Proteases from NMR Studies. Li Q, Kang C. Int J Mol Sci 21 E2527 (2020)
  19. Structure and Dynamics of Zika Virus Protease and Its Insights into Inhibitor Design. Li Q, Kang C. Biomedicines 9 1044 (2021)
  20. Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go. Saiz JC. Pharmaceuticals (Basel) 12 E127 (2019)
  21. Structures and Dynamics of Dengue Virus Nonstructural Membrane Proteins. Li Q, Kang C. Membranes (Basel) 12 231 (2022)
  22. A Review: The Antiviral Activity of Cyclic Peptides. Chia LY, Kumar PV, Maki MAA, Ravichandran G, Thilagar S. Int J Pept Res Ther 29 7 (2023)
  23. Animal venoms as a source of antiviral peptides active against arboviruses: a systematic review. Lima WG, Maia CQ, de Carvalho TS, Leite GO, Brito JCM, Godói IPD, de Lima ME, Ferreira JMS. Arch Virol 167 1763-1772 (2022)
  24. Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention. Blight J, Alves E, Reyes-Sandoval A. Vaccines (Basel) 7 E203 (2019)
  25. Covalent Antiviral Agents. Mirzaie S, Abdi F, GhavamiNejad A, Lu B, Wu XY. Adv Exp Med Biol 1322 285-312 (2021)
  26. Flavivirus proteases: The viral Achilles heel to prevent future pandemics. Teramoto T, Choi KH, Padmanabhan R. Antiviral Res 210 105516 (2023)
  27. Dengue virus NS4B protein as a target for developing antivirals. Li Q, Kang C. Front Cell Infect Microbiol 12 959727 (2022)
  28. Immune Recognition versus Immune Evasion Systems in Zika Virus Infection. Chan YT, Cheok YY, Cheong HC, Tang TF, Sulaiman S, Hassan J, Looi CY, Tan KK, AbuBakar S, Wong WF. Biomedicines 11 642 (2023)

Articles citing this publication (85)

  1. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Lei J, Lei J, Hansen G, Nitsche C, Klein CD, Zhang L, Hilgenfeld R. Science 353 503-505 (2016)
  2. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, Huang R, Koetzner CA, Allen CA, Jones SA, Chen H, Zhang NN, Tian M, Gao F, Lin Q, Banavali N, Zhou J, Boles N, Xia M, Kramer LD, Qin CF, Li H. Cell Res 27 1046-1064 (2017)
  3. Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Phoo WW, Li Y, Zhang Z, Lee MY, Loh YR, Tan YB, Ng EY, Lescar J, Kang C, Luo D. Nat Commun 7 13410 (2016)
  4. Crystal structure of unlinked NS2B-NS3 protease from Zika virus. Zhang Z, Li Y, Loh YR, Phoo WW, Hung AW, Kang C, Luo D. Science 354 1597-1600 (2016)
  5. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease. Brecher M, Li Z, Liu B, Zhang J, Koetzner CA, Alifarag A, Jones SA, Lin Q, Kramer LD, Li H. PLoS Pathog 13 e1006411 (2017)
  6. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Lee H, Ren J, Nocadello S, Rice AJ, Ojeda I, Light S, Minasov G, Vargas J, Nagarathnam D, Anderson WF, Johnson ME. Antiviral Res 139 49-58 (2017)
  7. Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: inhibition kinetics and docking studies. de Sousa LR, Wu H, Nebo L, Fernandes JB, da Silva MF, Kiefer W, Kanitz M, Bodem J, Diederich WE, Schirmeister T, Vieira PC. Bioorg Med Chem 23 466-470 (2015)
  8. NMR analysis of a novel enzymatically active unlinked dengue NS2B-NS3 protease complex. Kim YM, Gayen S, Kang C, Joy J, Huang Q, Chen AS, Wee JL, Ang MJ, Lim HA, Hung AW, Li R, Noble CG, Lee le T, Yip A, Wang QY, Chia CS, Hill J, Shi PY, Keller TH. J Biol Chem 288 12891-12900 (2013)
  9. Novel dengue virus NS2B/NS3 protease inhibitors. Wu H, Bock S, Snitko M, Berger T, Weidner T, Holloway S, Kanitz M, Diederich WE, Steuber H, Walter C, Hofmann D, Weißbrich B, Spannaus R, Acosta EG, Bartenschlager R, Engels B, Schirmeister T, Bodem J. Antimicrob Agents Chemother 59 1100-1109 (2015)
  10. Discovery, X-ray Crystallography and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. Yao Y, Huo T, Lin YL, Nie S, Wu F, Hua Y, Wu J, Kneubehl AR, Vogt MB, Rico-Hesse R, Song Y. J Am Chem Soc 141 6832-6836 (2019)
  11. Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease. Kumar A, Liang B, Aarthy M, Singh SK, Garg N, Mysorekar IU, Giri R. ACS Omega 3 18132-18141 (2018)
  12. Structural Dynamics of Zika Virus NS2B-NS3 Protease Binding to Dipeptide Inhibitors. Li Y, Zhang Z, Phoo WW, Loh YR, Wang W, Liu S, Chen MW, Hung AW, Keller TH, Luo D, Kang C. Structure 25 1242-1250.e3 (2017)
  13. Solution conformations of Zika NS2B-NS3pro and its inhibition by natural products from edible plants. Roy A, Lim L, Srivastava S, Lu Y, Song J. PLoS One 12 e0180632 (2017)
  14. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease. Li Z, Sakamuru S, Huang R, Brecher M, Koetzner CA, Zhang J, Chen H, Qin CF, Zhang QY, Zhou J, Kramer LD, Xia M, Li H. Antiviral Res 150 217-225 (2018)
  15. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. Coutard B, Decroly E, Li C, Sharff A, Lescar J, Bricogne G, Barral K. Antiviral Res 106 61-70 (2014)
  16. Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus. Rothan HA, Bahrani H, Rahman NA, Yusof R. BMC Microbiol 14 140 (2014)
  17. Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Lai H, Dou D, Aravapalli S, Teramoto T, Lushington GH, Mwania TM, Alliston KR, Eichhorn DM, Padmanabhan R, Groutas WC. Bioorg Med Chem 21 102-113 (2013)
  18. The dengue virus NS2B-NS3 protease retains the closed conformation in the complex with BPTI. Chen WN, Loscha KV, Nitsche C, Graham B, Otting G. FEBS Lett 588 2206-2211 (2014)
  19. A small compound targeting the interaction between nonstructural proteins 2B and 3 inhibits dengue virus replication. Pambudi S, Kawashita N, Phanthanawiboon S, Omokoko MD, Masrinoul P, Yamashita A, Limkittikul K, Yasunaga T, Takagi T, Ikuta K, Kurosu T. Biochem Biophys Res Commun 440 393-398 (2013)
  20. Research Support, Non-U.S. Gov't Binding mode of the activity-modulating C-terminal segment of NS2B to NS3 in the dengue virus NS2B-NS3 protease. de la Cruz L, Chen WN, Graham B, Otting G. FEBS J 281 1517-1533 (2014)
  21. Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold. Aravapalli S, Lai H, Teramoto T, Alliston KR, Lushington GH, Ferguson EL, Padmanabhan R, Groutas WC. Bioorg Med Chem 20 4140-4148 (2012)
  22. Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. Lai H, Sridhar Prasad G, Padmanabhan R. Antiviral Res 97 74-80 (2013)
  23. Increasing Clinical Severity during a Dengue Virus Type 3 Cuban Epidemic: Deep Sequencing of Evolving Viral Populations. Rodriguez-Roche R, Blanc H, Bordería AV, Díaz G, Henningsson R, Gonzalez D, Santana E, Alvarez M, Castro O, Fontes M, Vignuzzi M, Guzman MG. J Virol 90 4320-4333 (2016)
  24. Structural characterization of the linked NS2B-NS3 protease of Zika virus. Li Y, Phoo WW, Loh YR, Zhang Z, Ng EY, Wang W, Keller TH, Luo D, Kang C. FEBS Lett 591 2338-2347 (2017)
  25. Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases. Prusis P, Junaid M, Petrovska R, Yahorava S, Yahorau A, Katzenmeier G, Lapins M, Wikberg JE. Biochem Biophys Res Commun 434 767-772 (2013)
  26. NMR and MD Studies Reveal That the Isolated Dengue NS3 Protease Is an Intrinsically Disordered Chymotrypsin Fold Which Absolutely Requests NS2B for Correct Folding and Functional Dynamics. Gupta G, Lim L, Song J. PLoS One 10 e0134823 (2015)
  27. Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo. Li Z, Lang Y, Sakamuru S, Samrat S, Trudeau N, Kuo L, Rugenstein N, Tharappel A, D'Brant L, Koetzner CA, Hu S, Zhang J, Huang R, Kramer LD, Butler D, Xia M, Li H. Emerg Microbes Infect 9 2404-2416 (2020)
  28. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity. Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y. Bioorg Med Chem Lett 27 3586-3590 (2017)
  29. C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease. Behnam MA, Nitsche C, Vechi SM, Klein CD. ACS Med Chem Lett 5 1037-1042 (2014)
  30. Secondary Structure and Membrane Topology of the Full-Length Dengue Virus NS4B in Micelles. Li Y, Wong YL, Lee MY, Li Q, Wang QY, Lescar J, Shi PY, Kang C. Angew Chem Int Ed Engl 55 12068-12072 (2016)
  31. Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses. Braun NJ, Quek JP, Huber S, Kouretova J, Rogge D, Lang-Henkel H, Cheong EZK, Chew BLA, Heine A, Luo D, Steinmetzer T. ChemMedChem 15 1439-1452 (2020)
  32. Curcumin Allosterically Inhibits the Dengue NS2B-NS3 Protease by Disrupting Its Active Conformation. Lim L, Dang M, Roy A, Kang J, Song J. ACS Omega 5 25677-25686 (2020)
  33. Direct evidence of a low barrier hydrogen bond in the catalytic triad of a Serine protease. Agback P, Agback T. Sci Rep 8 10078 (2018)
  34. Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease. Sarwar MW, Riaz A, Dilshad SMR, Al-Qahtani A, Nawaz-Ul-Rehman MS, Mubin M. BMC Struct Biol 18 6 (2018)
  35. Capturing conformational States in proteins using sparse paramagnetic NMR data. Pilla KB, Leman JK, Otting G, Huber T. PLoS One 10 e0127053 (2015)
  36. Identification of covalent active site inhibitors of dengue virus protease. Koh-Stenta X, Joy J, Wang SF, Kwek PZ, Wee JL, Wan KF, Gayen S, Chen AS, Kang C, Lee MA, Poulsen A, Vasudevan SG, Hill J, Nacro K. Drug Des Devel Ther 9 6389-6399 (2015)
  37. Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease. Liu H, Wu R, Sun Y, Ye Y, Chen J, Luo X, Shen X, Liu H. Bioorg Med Chem 22 6344-6352 (2014)
  38. Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors. Timiri AK, Selvarasu S, Kesherwani M, Vijayan V, Sinha BN, Devadasan V, Jayaprakash V. Bioorg Chem 62 74-82 (2015)
  39. Viral proteases: Structure, mechanism and inhibition. Zephyr J, Kurt Yilmaz N, Schiffer CA. Enzymes 50 301-333 (2021)
  40. Allosteric pocket of the dengue virus (serotype 2) NS2B/NS3 protease: In silico ligand screening and molecular dynamics studies of inhibition. Mukhametov A, Newhouse EI, Aziz NA, Saito JA, Alam M. J Mol Graph Model 52 103-113 (2014)
  41. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Balasubramanian A, Manzano M, Teramoto T, Pilankatta R, Padmanabhan R. Antiviral Res 134 6-16 (2016)
  42. Integrative Protein Modeling in RosettaNMR from Sparse Paramagnetic Restraints. Kuenze G, Bonneau R, Leman JK, Meiler J. Structure 27 1721-1734.e5 (2019)
  43. Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly. VanBlargan LA, Davis KA, Dowd KA, Akey DL, Smith JL, Pierson TC. J Virol 89 8632-8642 (2015)
  44. Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells. Wu DW, Mao F, Ye Y, Li J, Xu CL, Luo XM, Chen J, Shen X. Acta Pharmacol Sin 36 1126-1136 (2015)
  45. Rational discovery of dengue type 2 non-competitive inhibitors. Heh CH, Othman R, Buckle MJ, Sharifuddin Y, Yusof R, Rahman NA. Chem Biol Drug Des 82 1-11 (2013)
  46. Lyso-myristoyl phosphatidylcholine micelles sustain the activity of Dengue non-structural (NS) protein 3 protease domain fused with the full-length NS2B. Huang Q, Li Q, Joy J, Chen AS, Ruiz-Carrillo D, Hill J, Lescar J, Kang C. Protein Expr Purif 92 156-162 (2013)
  47. Evaluation of the Leaf Essential Oil from Artemisia vulgaris and Its Larvicidal and Repellent Activity against Dengue Fever Vector Aedes aegypti-An Experimental and Molecular Docking Investigation. Balasubramani S, Sabapathi G, Moola AK, Solomon RV, Venuvanalingam P, Bollipo Diana RK. ACS Omega 3 15657-15665 (2018)
  48. Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease. Kuiper BD, Slater K, Spellmon N, Holcomb J, Medapureddy P, Muzzarelli KM, Yang Z, Ovadia R, Amblard F, Kovari IA, Schinazi RF, Kovari LC. Biochem Biophys Res Commun 492 668-673 (2017)
  49. Sequence, structure and function relationships in flaviviruses as assessed by evolutive aspects of its conserved non-structural protein domains. da Fonseca NJ, Lima Afonso MQ, Pedersolli NG, de Oliveira LC, Andrade DS, Bleicher L. Biochem Biophys Res Commun 492 565-571 (2017)
  50. Small neutral Gd(iii) tags for distance measurements in proteins by double electron-electron resonance experiments. Mahawaththa MC, Lee MD, Giannoulis A, Adams LA, Feintuch A, Swarbrick JD, Graham B, Nitsche C, Goldfarb D, Otting G. Phys Chem Chem Phys 20 23535-23545 (2018)
  51. New binding site conformations of the dengue virus NS3 protease accessed by molecular dynamics simulation. de Almeida H, Bastos IM, Ribeiro BM, Maigret B, Santana JM. PLoS One 8 e72402 (2013)
  52. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection. Pathak N, Lai ML, Chen WY, Hsieh BW, Yu GY, Yang JM. BMC Bioinformatics 18 548 (2017)
  53. Structure and sequence based functional annotation of Zika virus NS2b protein: Computational insights. Aguilera-Pesantes D, Méndez MA. Biochem Biophys Res Commun 492 659-667 (2017)
  54. In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus. Li Z, Xu J, Lang Y, Wu X, Hu S, Samrat SK, Tharappel AM, Kuo L, Butler D, Song Y, Zhang QY, Zhou J, Li H. Acta Pharm Sin B 12 1662-1670 (2022)
  55. A single amino acid substitution in the NS4B protein of Dengue virus confers enhanced virus growth and fitness in human cells in vitro through IFN-dependent host response. Bui TT, Moi ML, Nabeshima T, Takemura T, Nguyen TT, Nguyen LN, Pham HTT, Nguyen TTT, Manh DH, Dumre SP, Mizukami S, Hirayama K, Tajima S, Le MTQ, Aoyagi K, Hasebe F, Morita K. J Gen Virol 99 1044-1057 (2018)
  56. Chalcones from Angelica keiskei (ashitaba) inhibit key Zika virus replication proteins. Mottin M, Caesar LK, Brodsky D, Mesquita NCMR, de Oliveira KZ, Noske GD, Sousa BKP, Ramos PRPS, Jarmer H, Loh B, Zorn KM, Foil DH, Torres PM, Guido RVC, Oliva G, Scholle F, Ekins S, Cech NB, Andrade CH, Laster SM. Bioorg Chem 120 105649 (2022)
  57. Discovering key residues of dengue virus NS2b-NS3-protease: New binding sites for antiviral inhibitors design. Aguilera-Pesantes D, Robayo LE, Méndez PE, Mollocana D, Marrero-Ponce Y, Torres FJ, Méndez MA. Biochem Biophys Res Commun 492 631-642 (2017)
  58. Discovery of novel West Nile Virus protease inhibitor based on isobenzonafuranone and triazolic derivatives of eugenol and indan-1,3-dione scaffolds. de Oliveira AS, Gazolla PAR, Oliveira AFCDS, Pereira WL, de S Viol LC, Maia AFDS, Santos EG, da Silva ÍEP, Mendes TAO, da Silva AM, Dias RS, da Silva CC, Polêto MD, Teixeira RR, de Paula SO. PLoS One 14 e0223017 (2019)
  59. Reaction mechanism of the dengue virus serine protease: a QM/MM study. Lima MC, Seabra GM. Phys Chem Chem Phys 18 30288-30296 (2016)
  60. Ethyl 4-(4-methylphenyl)-4-pentenoate from Vetiveria zizanioides Inhibits Dengue NS2B-NS3 Protease and Prevents Viral Assembly: A Computational Molecular Dynamics and Docking Study. Lavanya P, Ramaiah S, Anbarasu A. Cell Biochem Biophys 74 337-351 (2016)
  61. Identification of potential Zika virus NS2B-NS3 protease inhibitors via docking, molecular dynamics and consensus scoring-based virtual screening. Bowen LR, Li DJ, Nola DT, Anderson MO, Heying M, Groves AT, Eagon S. J Mol Model 25 194 (2019)
  62. An inhibition model of BPTI to unlinked dengue virus NS2B-NS3 protease. Li H, Zhu L, Hou S, Yang J, Wang J, Liu J. FEBS Lett 588 2794-2799 (2014)
  63. Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence. Piccirillo E, Merget B, Sotriffer CA, do Amaral AT. J Comput Aided Mol Des 30 251-270 (2016)
  64. In Silico Prediction of the Phosphorylation of NS3 as an Essential Mechanism for Dengue Virus Replication and the Antiviral Activity of Quercetin. Alomair L, Almsned F, Ullah A, Jafri MS. Biology (Basel) 10 1067 (2021)
  65. Product release is rate-limiting for catalytic processing by the Dengue virus protease. Shannon AE, Pedroso MM, Chappell KJ, Watterson D, Liebscher S, Kok WM, Fairlie DP, Schenk G, Young PR. Sci Rep 6 37539 (2016)
  66. 1H, 13C and 15N resonance assignment of backbone and IVL-methyl side chain of the S135A mutant NS3pro/NS2B protein of Dengue II virus reveals unique secondary structure features in solution. Agback P, Lesovoy DM, Han X, Sun R, Sandalova T, Agback T, Achour A, Orekhov VY. Biomol NMR Assign 16 135-145 (2022)
  67. Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors. Pant S, Jena NR. Eur J Pharm Sci 167 106012 (2021)
  68. Transplantation of a hydrogen bonding network from West Nile virus protease onto Dengue-2 protease improves catalytic efficiency and sheds light on substrate specificity. Doan DN, Li KQ, Basavannacharya C, Vasudevan SG, Madhusudhan MS. Protein Eng Des Sel 25 843-850 (2012)
  69. A competition smFRET assay to study ligand-induced conformational changes of the dengue virus protease. Maus H, Hinze G, Hammerschmidt SJ, Basché T, Schirmeister T. Protein Sci 32 e4526 (2023)
  70. Boroleucine-Derived Covalent Inhibitors of the ZIKV Protease. Braun NJ, Huber S, Schmacke LC, Heine A, Steinmetzer T. ChemMedChem 18 e202200336 (2023)
  71. Design, synthesis, in vitro, in silico, and SAR studies of flavone analogs towards anti-dengue activity. Patigo A, Hengphasatporn K, Cao V, Paunrat W, Vijara N, Chokmahasarn T, Maitarad P, Rungrotmongkol T, Shigeta Y, Boonyasuppayakorn S, Khotavivattana T. Sci Rep 12 21646 (2022)
  72. Letter Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases. Jones CL, Yeung BK, Manjunatha U, Shi PY, Bodenreider C, Diagana TT. Nat Rev Drug Discov 14 442-444 (2015)
  73. Myricetin Allosterically Inhibits the Dengue NS2B-NS3 Protease by Disrupting the Active and Locking the Inactive Conformations. Dang M, Lim L, Roy A, Song J. ACS Omega 7 2798-2808 (2022)
  74. The reaction mechanism of Zika virus NS2B/NS3 serine protease inhibition by dipeptidyl aldehyde: a QM/MM study. Nutho B, Mulholland AJ, Rungrotmongkol T. Phys Chem Chem Phys 21 14945-14956 (2019)
  75. Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. Zephyr J, Rao DN, Johnson C, Shaqra AM, Nalivaika EA, Jordan A, Kurt Yilmaz N, Ali A, Schiffer CA. Bioorg Chem 131 106269 (2023)
  76. Anti-dengue drug: viral polyprotein, a potential target. Mahmood SU, Mushtaq M, Syed MJ. Drug Des Devel Ther 10 2047-2048 (2016)
  77. Antiviral Activity of Flavonoids from Geopropolis of the Brazilian Jandaira Bee against Zika and Dengue Viruses. Silva PGD, Chaves EJF, Silva TMS, Rocha GB, Dantas WM, Oliveira RN, Pena LJ. Pharmaceutics 15 2494 (2023)
  78. Cationic Geminoid Peptide Amphiphiles Inhibit DENV2 Protease, Furin, and Viral Replication. Damen M, Izidoro MA, Okamoto DN, Oliveira LCG, Amatdjais-Groenen HIV, van Dongen SFM, van Cleef KWR, van Rij RP, Dieteren CEJ, Gironés D, van Buuren BNM, Martina BEE, Osterhaus ADME, Juliano L, Scholte BJ, Feiters MC. Molecules 27 3217 (2022)
  79. Combined NMR and molecular dynamics conformational filter identifies unambiguously dynamic ensembles of Dengue protease NS2B/NS3pro. Agback T, Lesovoy D, Han X, Lomzov A, Sun R, Sandalova T, Orekhov VY, Achour A, Agback P. Commun Biol 6 1193 (2023)
  80. Data on docking of phytoconstituents of Actinidia deliciosa on dengue viral targets. Chandani SR, Lokhande KB, Swamy KV, Nanda RK, Chitlange SS. Data Brief 25 103996 (2019)
  81. Designing photoaffinity tool compounds for the investigation of the DENV NS2B-NS3 protease allosteric binding pocket. Maus H, Gellert A, Englert OR, Chen JX, Schirmeister T, Barthels F. RSC Med Chem 14 2365-2379 (2023)
  82. Drugs to limit Zika virus infection and implication for maternal-fetal health. Kumar A, Kumar D, Jose J, Giri R, Mysorekar IU. Front Virol 2 928599 (2022)
  83. Obstructing Salmonella typhi's virulence in eukaryotic cells through design of its SipB protein antagonists. Ameji JP, Uzairu A, Shallangwa GA, Uba S. J Taibah Univ Med Sci 18 726-736 (2023)
  84. Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: structure-based virtual screening, molecular docking and molecular dynamics simulation studies. Purohit P, Sahoo S, Panda M, Sahoo PS, Meher BR. J Mol Model 28 365 (2022)
  85. The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase. Boonyasuppayakorn S, Saelee T, Huynh TNT, Hairani R, Hengphasatporn K, Loeanurit N, Cao V, Vibulakhaophan V, Siripitakpong P, Kaur P, Chu JJH, Tunghirun C, Choksupmanee O, Chimnaronk S, Shigeta Y, Rungrotmongkol T, Chavasiri W. Sci Rep 13 4891 (2023)


Quick links